Sipuleucel‐T is a personalized, autologous immunotherapy that activates the patient’s immune system to target prostatic acid phosphatase (PAP)–expressing tumor cells and has demonstrated survival benefit in patients with nonopioid requiring mCRPC. This evidence concerns the gene ACP3 and neoplasm.